Trials / Completed
CompletedNCT01529411
Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer
Randomized Phase II Study of Vinflunine as Maintenance Monotherapy in Patients With Advanced or Metastatic Urothelial Cancer That Obtains Clinical Benefit of the First Line With Cisplatin-gemcitabine Combination
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Spanish Oncology Genito-Urinary Group · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a clinical trial to evaluate the efficacy and safety of the drug vinflunine administered after the standard treatment of the combination gemcitabine+cisplatin, when it has reached stabilization or response of the disease, as the first treatment inmeditely after the diagnosis of advanced or metastatic urothelial cancer.
Detailed description
Vinflunine is a drug recently approved in Europe for the treatment of advanced or metastatic urothelial cancer after platinum-failure. It has proved to improve the survival results compared with the best suportive care. In adition, the tolerability was favourable, specially for not leading appearance of neuropathy nor other cumulative toxic effects. In this study, it is proposed to test the feasibility, in terms of tolerability and efficacy of monotherapy with vinflunine in patients who, after completing the first-line cisplatin-based treatment for Transitional Cell Carcinoma of the Urothelial Tract (CCTU), have reached a stabilization or objective response. In order to have an adequate control group in the proposed design will be a phase II trial in which one group will receive standard management (follow-up until progression disease).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vinflunine | Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance \< 60ml/min). |
| OTHER | Undefined (standard care) | All the current interventions used by each institution for the study disease. |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-02-01
- Completion
- 2014-12-01
- First posted
- 2012-02-08
- Last updated
- 2019-04-04
Locations
20 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01529411. Inclusion in this directory is not an endorsement.